EQL Pharma AB (publ) (STO:EQL)

Aspen Technology Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 2.67 billion. The enterprise value is 3.04 billion.

Market Cap	2.67B
Enterprise Value	3.04B

Important Dates

The last earnings date was Monday, July 28, 2025.

Earnings Date	Jul 28, 2025
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.06 million shares outstanding. The number of shares has increased by 0.34% in one year.

Current Share Class	29.06M
Shares Outstanding	29.06M
Shares Change (YoY)	+0.34%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.36%
Owned by Institutions (%)	11.30%
Float	21.27M

Valuation Ratios

The trailing PE ratio is 63.82 and the forward PE ratio is 42.55.

PE Ratio	63.82
Forward PE	42.55
PS Ratio	7.15
PB Ratio	12.08
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.30, with an EV/FCF ratio of -98.91.

EV / Earnings	70.59
EV / Sales	8.15
EV / EBITDA	39.30
EV / EBIT	45.19
EV / FCF	-98.91

Financial Position

The company has a current ratio of 1.81, with a Debt / Equity ratio of 2.06.

Current Ratio	1.81
Quick Ratio	0.97
Debt / Equity	2.06
Debt / EBITDA	5.88
Debt / FCF	-14.81
Interest Coverage	5.46

Financial Efficiency

Return on equity (ROE) is 21.63% and return on invested capital (ROIC) is 8.64%.

Return on Equity (ROE)	21.63%
Return on Assets (ROA)	7.12%
Return on Invested Capital (ROIC)	8.64%
Return on Capital Employed (ROCE)	11.46%
Revenue Per Employee	17.79M
Profits Per Employee	2.05M
Employee Count	21
Asset Turnover	0.63
Inventory Turnover	1.53

Taxes

In the past 12 months, EQL Pharma AB has paid 11.23 million in taxes.

Income Tax	11.23M
Effective Tax Rate	20.66%

Stock Price Statistics

The stock price has increased by +77.86% in the last 52 weeks. The beta is 0.66, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.66
52-Week Price Change	+77.86%
50-Day Moving Average	88.59
200-Day Moving Average	78.59
Relative Strength Index (RSI)	62.50
Average Volume (20 Days)	19,849

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 373.52 million and earned 43.12 million in profits. Earnings per share was 1.44.

Revenue	373.52M
Gross Profit	155.95M
Operating Income	67.37M
Pretax Income	54.36M
Net Income	43.12M
EBITDA	75.68M
EBIT	67.37M
Earnings Per Share (EPS)	1.44

Balance Sheet

The company has 82.40 million in cash and 455.71 million in debt, giving a net cash position of -373.31 million or -12.84 per share.

Cash & Cash Equivalents	82.40M
Total Debt	455.71M
Net Cash	-373.31M
Net Cash Per Share	-12.84
Equity (Book Value)	221.03M
Book Value Per Share	7.61
Working Capital	179.23M

Cash Flow

In the last 12 months, operating cash flow was -24.65 million and capital expenditures -6.13 million, giving a free cash flow of -30.78 million.

Operating Cash Flow	-24.65M
Capital Expenditures	-6.13M
Free Cash Flow	-30.78M
FCF Per Share	-1.06

Margins

Gross margin is 41.75%, with operating and profit margins of 18.04% and 11.55%.

Gross Margin	41.75%
Operating Margin	18.04%
Pretax Margin	14.55%
Profit Margin	11.55%
EBITDA Margin	20.26%
EBIT Margin	18.04%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.34%
Shareholder Yield	n/a
Earnings Yield	1.61%
FCF Yield	-1.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

EQL Pharma AB has an Altman Z-Score of 3.12 and a Piotroski F-Score of 3.

Altman Z-Score	3.12
Piotroski F-Score	3